COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Efficacy of Ginsana in Improving Half-time Hemoglobin Re-oxygenation in Healthy People

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02182882
Recruitment Status : Completed
First Posted : July 8, 2014
Last Update Posted : July 8, 2014
Information provided by (Responsible Party):
Boehringer Ingelheim

Brief Summary:
Study to assess the efficacy of ginsana in improving half-time hemoglobin re-oxygenation in healthy, recreational sportspeople and to assess the safety of the product

Condition or disease Intervention/treatment Phase
Healthy Drug: GINSANA Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 29 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: Efficacy of Ginsana in Improving Half -Time Hemoglobin Re-oxygenation in Recreational Sportspeople: a Double Blind, Placebo Controlled Pilot Study
Study Start Date : March 1999
Actual Primary Completion Date : October 1999

Arm Intervention/treatment
Experimental: GINSANA Drug: GINSANA
Placebo Comparator: Placebo Drug: Placebo

Primary Outcome Measures :
  1. Change from baseline in half-time hemoglobin re-oxygenation by Near InfraRed Spectroscopy (NIRS) methodology [ Time Frame: Baseline, day 84 post first drug dispense ]

Secondary Outcome Measures :
  1. Change from baseline in half-time hemoglobin re-oxygenation by NIRS methodology [ Time Frame: Baseline, day 21, 42 and 63 post first drug dispense ]
  2. Maximum endurance time [ Time Frame: up to day 84 post first drug dispense ]
  3. Change from baseline in respiratory threshold [ Time Frame: Baseline, up to day 84 post first drug dispense ]
  4. Change from baseline in thiobarbituric acid (TBARS) [ Time Frame: Baseline, up to day 84 post first drug dispense ]
  5. Change from baseline in glutathion superdismutase / glutathion superdismutase oxidised (GSA/GSSG) [ Time Frame: Baseline, up to day 84 post first drug dispense ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Male and female volunteers between 18 and 40 years old
  • Females must test negative for pregnancy
  • Recreational athletes according to the american college of sports medicine (ACSM) definition
  • Familiar with the cycle ergometer exercise methodology
  • Written inform consent according to good clinical practice (GCP) and local regulations

Exclusion Criteria:

  • Pre-treatment (less than 2 weeks prior to inclusion in this trial) and/or concomitant treatment with any drug that any drug that could have influence the trail methodology
  • Alcohol and drug abuse (as defined in Diagnostic and Statistic Manual IV( DSM-IV)) per subject verbal report
  • Smokers
  • Known hypertension
  • Known hypercholesterolemia (moderate/severe)
  • Female volunteers taking oral or injectable contraceptives
  • Female volunteers of child bearing potential not using adequate means of birth control, other than contraceptive pills [intrauterine devices (IUDs)]
  • Pregnancy and/or lactation
  • Liver and/or renal disease and/or vascular disease
  • Relevant allergy or known hypersensitivity to the investigational drug or its excipients
  • Participation in another clinical trial within the last 4 weeks and concurrent participation in another clinical trial

Layout table for additonal information
Responsible Party: Boehringer Ingelheim Identifier: NCT02182882    
Other Study ID Numbers: 1020.10
First Posted: July 8, 2014    Key Record Dates
Last Update Posted: July 8, 2014
Last Verified: July 2014